Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis

T Cell Immunity in Collagen Biosynthesis of Scleroderma

Progressive systemic sclerosis (SSc) is an immune-based disease that causes abnormal connective tissue growth of the skin and internal organs. At this point, there are no effective therapies for treating SSc. Thalidomide is a medication that has been shown to stimulate an immune response that reduces the body's synthesis of collagen, the main component of connective tissue. This study will determine the effectiveness of thalidomide in treating adults with SSc.

Study Overview

• Status: Terminated
• Conditions: Scleroderma, Systemic
• Intervention / Treatment: Drug: Thalidomide; Drug: Placebo thalidomide

Detailed Description

Progressive systemic sclerosis (SSc), also known as scleroderma, is a disease of the body's connective tissue. It is characterized by fibrosis of the skin, or formation of scar-like tissue, resulting in progressively increased restriction of joint range of motion. Fibrosis of internal organs also occurs, leading to irregular heart rhythms, acid reflux, and respiratory problems. Unfortunately, no therapies have been developed to effectively treat SSc.

The disease is believed to be an immunological disorder that affects T-helper type 2 (Th2) cells, which stimulate the production of antibodies and interleukin-4 (IL-4), a protein with profibrotic properties. T-helper type 1 (Th1) cells produce interferon-γ (IFN-γ), a protein that prevents fibroblast production of collagen, a primary component of the body's connective tissue. It is possible that shifting the disease's target from the Th2 cells to the Th1 cells may decrease collagen production, and thereby reduce fibrosis. Thalidomide is an immune modulatory drug that has been shown to stimulate production of Th1 cells. This study will evaluate the effectiveness of thalidomide in treating adults with SSc.

Following screening procedures, participants in this 48-week, double-blind study will be randomly assigned to receive placebo or thalidomide at a dose of 50 mg/day. The thalidomide dose will be increased to 100 mg/day at Week 2, then to 200 mg/day at Week 4, and finally to 300 mg/day at Week 6. Participants who experience dose intolerance will immediately switch to the previously tolerated dose. Inpatient hospital visits lasting 2 days will occur at the beginning of the study before starting thalidomide treatment and at Weeks 16 and 48. Assessments and procedures at these visits will include blood and urine collection, a physical exam, a chest X-ray, an electrocardiogram, a skin biopsy, and various questionnaires. Outpatient study visits will occur at Weeks 2, 4, 6, 8, 12, 18, 20 and then every 4 weeks until Week 44. Assessments will include measures of immune function, clinical disease, hypothalamic-pituitary-adrenal axis, and safety. Following the Week 48 inpatient visit, thalidomide will be tapered off over a 2-week period for all participants.

• Study Type: Interventional
• Enrollment (Actual): 30
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • New York
    • New York, New York, United States, 10016
      • New York University School of Medicine General Clinical Research Center, Bellevue Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Diagnosis of scleroderma
• Agrees to use an effective form of contraception for 1 month prior to study entry, throughout the study, and for 60 days after completing the study
• Positive serum anti-nuclear antibody titer

Exclusion Criteria:

• Systemic sclerosis-like illnesses associated with environmental, ingested, or injected agents or with other connective tissue diseases

• Significant existing damage to any of the following internal organs:

  • Kidneys, defined as a serum creatinine level greater than 2 mg/dl or renal crisis
  • Lungs, defined as needing supplemental oxygen
  • Heart, defined as left ventricular ejection fraction less than or equal to 40%
  • Gut, defined as pseudo-obstruction or malabsorption requiring total parental nutrition
• Concurrent interventional therapy that might independently influence the outcome of this trial (e.g., D-penicillamine, cyclosporine, interferon-γ, methotrexate, or photophorosis)
• Clinically significant and inadequately medically treated concurrent endocrine, blood, liver, lung, or kidney diseases
• Pregnant
• Recent drug or alcohol abuse
• Documented noncompliance
• Significant psychiatric history
• Therapy with another investigational drug within 4 weeks prior to study entry
• Screening laboratory results exceeding the following limits: hemoglobin level less than 7 gm/dl; white blood cell level less than 3,000/nl; platelet count less than 50/nl; alanine aminotransferase (ALT) level greater than 65 U/L; creatinine level greater than 2 mg/dl

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 1; Participants will receive thalidomide.	Drug: Thalidomide; Thalidomide at a dose of 50 mg/day. The dose will be increased to 100 mg/day at Week 2, then to 200 mg/day at Week 4, and finally to 300 mg/day at Week 6.
Placebo Comparator: 2; Participants will receive placebo thalidomide.	Drug: Placebo thalidomide; Participants will receive placebo thalidomide. The placebo dose will be increased through to Week 6.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Collagen mRNA levels in the skin	Measured at Weeks 16 and 48
In vivo collagen production	Measured at Weeks 16 and 48

Secondary Outcome Measures

Outcome Measure	Time Frame
Immune function	Measured at Weeks 4, 16, and 48
Clinical disease measures	Measured at Weeks 16 and 48
Hypothalamic-Pituitary-Adrenal (HPA) axis measures	Measured at Weeks 16 and 48
Safety measures	Measured at Weeks 4, 16, and 48

Collaborators and Investigators

• Sponsor: NYU Langone Health
• Collaborators: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
• Investigators: Principal Investigator: Stephen J. Oliver, MD, NYU Langone Health

Study record dates

Study Major Dates

• Study Start: August 1, 2000
• Study Completion (Actual): October 1, 2007

Study Registration Dates

• First Submitted: January 3, 2007
• First Submitted That Met QC Criteria: January 3, 2007
• First Posted (Estimate): January 4, 2007

Study Record Updates

• Last Update Posted (Estimate): March 11, 2016
• Last Update Submitted That Met QC Criteria: March 10, 2016
• Last Verified: March 1, 2016

More Information

Terms related to this study

• Keywords: Systemic Sclerosis; SSc; Progressive Systemic Sclerosis
• Additional Relevant MeSH Terms: Skin Diseases; Connective Tissue Diseases; Scleroderma, Systemic; Scleroderma, Diffuse; Physiological Effects of Drugs; Anti-Infective Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Anti-Bacterial Agents; Leprostatic Agents; Thalidomide
• Other Study ID Numbers: K23AR002187 (U.S. NIH Grant/Contract)